

Tamiflu[®] (oseltamivir) – First-Time Generic

- On August 3, 2016, the <u>FDA approved Natco Pharma's AB-rated</u> generic version of Roche's <u>Tamiflu</u> (oseltamivir) oral capsules, for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours, and for prophylaxis of influenza A and B in patients 1 year and older.
 - Tamiflu is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices.
 - Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (eg, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Tamiflu.
 - Tamiflu is not recommended for patients with end-stage renal disease not undergoing dialysis
- Based on a settlement agreement, Natco Pharma's partner, Alvogen, will be able to market generic Tamiflu before the expiration of the pediatric exclusivity period of February 23, 2017. Generic Tamiflu will be available as 30 mg, 45 mg, and 75 mg capsules.
 - Brand Tamiflu is also available as an oral suspension.
- According to IMS Health, Tamiflu oral capsules had U.S. sales of approximately \$403 million for 12 months ending in December 2015.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News[®] is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.